Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 11, 2025Scientific ReportsOpen Access

Added prognostic value of baseline pre-infusion 18F-FDG PET/CT in diffuse large B-cell lymphoma patients receiving chimeric antigen receptor T-cell therapy

View Full Paper
Ask AI
Bookmark
Share

Authors

SMSeyed Ali MirshahvaladAKAndres KohanRKRoshini Kulanthaivelu

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows pre-infusion PET/CT identifies residual disease and predicts progression-free survival in DLBCL patients receiving CAR-T therapy.

Key Points

  • To assess the prognostic value of pre-infusion 18F-FDG PET/CT in DLBCL patients undergoing CAR-T therapy.
  • Retrospective analysis of 159 patients receiving CAR-T therapy from 2018 to 2023.
  • Evaluation of pre-infusion 18F-FDG PET/CT with focus on standardized uptake values and Deauville scores.
  • Survival analyses to determine predictors of progression-free survival and overall survival.
  • 91% of DLBCL patients showed significant residual disease based on pre-infusion PET/CT.
  • Median progression-free survival was six months post-CAR-T treatment.
  • Total lesion glycolysis and serum LDH were independent predictors of progression-free survival.

Cite This Study

Mirshahvalad et al. (2025) studied this question.

synapsesocial.com/papers/69252e9ec0ce034ddc3563fchttps://doi.org/10.1038/s41598-025-23159-9
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1[18F]FDG-PET/CT in DLBCL-patients treated with CAR-T cell therapy: potential for defining patient prognosis2025
  2. 2Systematic review and meta−analysis of PET−based prognostic metrics in CAR−T treatment of DLBCL2026 · 2 citations
  3. 3Predicting survival outcomes in CAR-t treated B-cell lymphoma by combining PET/CT imagingand clinical features2025
  4. 4Baseline and interim 18F-FDG PET/CT metabolic parameters predict the efficacy and survival in patients with diffuse large B-cell lymphoma2024 · 15 citations
  5. 5FDG-PET/CT is a powerful tool to predict and evaluate response to chimeric antigen receptor (CAR) T-cell therapy in Non-Hodgkin-Lymphoma (NHL)2024